Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aztreonam-avibactam versus meropenem with or without colistin for serious gram-negative infections
2017-002742-68Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aztreonam + avibactam in Intra-abdominal infection (IAI), hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 1 more (2 arms), sponsored by Pfizer. Primary endpoint: Clinical cure at Test of Cure in Intent-To-Treat and Clinically Evaluable populations. Started Mar 2018; status: completed.
02
Drugs
aztreonam + avibactam
03
Conditions
Intra-abdominal infection (IAI)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Gram-negative bacterial infection
Beyond the preview
Go deeper on 2017-002742-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002742-68.